abrdn plc Purchases 915 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Posted by on May 24th, 2023

abrdn plc boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 7.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 13,124 shares of the biopharmaceutical company’s stock after acquiring an additional 915 shares during the period. abrdn plc’s holdings in Alnylam Pharmaceuticals were worth $3,119,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. grew its stake in Alnylam Pharmaceuticals by 9.4% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 11,850 shares of the biopharmaceutical company’s stock valued at $1,935,000 after buying an additional 1,017 shares in the last quarter. MetLife Investment Management LLC purchased a new position in Alnylam Pharmaceuticals during the 1st quarter valued at about $1,268,000. Panagora Asset Management Inc. grew its stake in Alnylam Pharmaceuticals by 96.4% during the first quarter. Panagora Asset Management Inc. now owns 6,565 shares of the biopharmaceutical company’s stock valued at $1,072,000 after acquiring an additional 3,223 shares in the last quarter. Great West Life Assurance Co. Can increased its holdings in Alnylam Pharmaceuticals by 21.2% during the 1st quarter. Great West Life Assurance Co. Can now owns 62,369 shares of the biopharmaceutical company’s stock worth $10,786,000 after acquiring an additional 10,892 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Alnylam Pharmaceuticals by 1.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 181,271 shares of the biopharmaceutical company’s stock valued at $29,601,000 after purchasing an additional 2,111 shares during the period.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of recent analyst reports. Oppenheimer lowered their price objective on Alnylam Pharmaceuticals from $256.00 to $249.00 and set an “outperform” rating on the stock in a research report on Friday, February 24th. JPMorgan Chase & Co. decreased their price objective on shares of Alnylam Pharmaceuticals from $200.00 to $196.00 and set a “neutral” rating on the stock in a research report on Friday, March 3rd. BMO Capital Markets raised shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $200.00 to $250.00 in a research note on Friday, May 5th. 92 Resources restated an “initiates” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 26th. Finally, Canaccord Genuity Group cut their target price on shares of Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating for the company in a research report on Friday, February 24th. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $247.20.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,839 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $194.59, for a total transaction of $357,851.01. Following the completion of the transaction, the chief marketing officer now directly owns 6,800 shares of the company’s stock, valued at approximately $1,323,212. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CMO Pushkal Garg sold 1,839 shares of the company’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $357,851.01. Following the transaction, the chief marketing officer now owns 6,800 shares in the company, valued at approximately $1,323,212. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 7,615 shares of the firm’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $194.59, for a total transaction of $1,481,802.85. Following the sale, the chief executive officer now owns 30,332 shares of the company’s stock, valued at $5,902,303.88. The disclosure for this sale can be found here. Insiders have sold 35,871 shares of company stock valued at $7,131,842 in the last three months. 1.40% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Trading Down 0.6 %

NASDAQ:ALNY opened at $191.83 on Wednesday. The company has a 50-day moving average price of $199.27 and a 200-day moving average price of $212.24. The stock has a market cap of $23.89 billion, a price-to-earnings ratio of -22.07 and a beta of 0.48. Alnylam Pharmaceuticals, Inc. has a 12 month low of $120.43 and a 12 month high of $242.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.57. The firm had revenue of $319.29 million for the quarter, compared to the consensus estimate of $312.53 million. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 93.13%. The business’s revenue for the quarter was up 49.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.00) EPS. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.59 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

See Also

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.